Cargando…

Heterogeneity of miR-10b expression in circulating tumor cells

Circulating tumor cells (CTCs) in the blood of cancer patients are recognized as important potential targets for future anticancer therapies. As mediators of metastatic spread, CTCs are also promising to be used as ‘liquid biopsy’ to aid clinical decision-making. Recent work has revealed potentially...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gasch, Christin, Plummer, Prue N., Jovanovic, Lidija, McInnes, Linda M., Wescott, David, Saunders, Christobel M., Schneeweiss, Andreas, Wallwiener, Markus, Nelson, Colleen, Spring, Kevin J., Riethdorf, Sabine, Thompson, Erik W., Pantel, Klaus, Mellick, Albert S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629160/ https://www.ncbi.nlm.nih.gov/pubmed/26522916 http://dx.doi.org/10.1038/srep15980

Ejemplares similares

Clinical Implications of Circulating Tumor Cells of Breast Cancer Patients: Role of Epithelial–Mesenchymal Plasticity
por: McInnes, Linda M., et al.
Publicado: (2015)

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
por: Wallwiener, Markus, et al.
Publicado: (2015)

The dynamic range of circulating tumor DNA in metastatic breast cancer
por: Heidary, Maryam, et al.
Publicado: (2014)

HER2-targeted therapy influences CTC status in metastatic breast cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients
por: Wallwiener, Markus, et al.
Publicado: (2014)

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
por: Riethdorf, Sabine, et al.
Publicado: (2009)

The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer
por: Stefanovic, Stefan, et al.
Publicado: (2020)

Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer
por: Gorges, Tobias M., et al.
Publicado: (2016)

Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells
por: Tachtsidis, A., et al.
Publicado: (2016)

Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence
por: Knipper, Sophie, et al.
Publicado: (2021)

Circulating tumor cells and extracellular vesicles as liquid biopsy markers in neuro-oncology: prospects and limitations
por: Westphal,, Manfred, et al.
Publicado: (2022)

The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer
por: Riethdorf, Sabine, et al.
Publicado: (2017)

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
por: Müller, V., et al.
Publicado: (2021)

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch(®) System and the AdnaTest(®)
por: Gorges, Tobias M., et al.
Publicado: (2016)

Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker
por: Ningsi, Retno, et al.
Publicado: (2022)

The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy
por: Rink, Michael, et al.
Publicado: (2020)

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection
por: von Felden, Johann, et al.
Publicado: (2017)

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
por: Müller, Volkmar, et al.
Publicado: (2012)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

Impact of label-free technologies in head and neck cancer circulating tumour cells
por: Kulasinghe, Arutha, et al.
Publicado: (2016)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Müller, Volkmar, et al.
Publicado: (2011)

Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma
por: Fründt, Thorben, et al.
Publicado: (2022)

Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer
por: Abdalla, Thaer S. A., et al.
Publicado: (2021)

Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)
por: Bergmann, Sonja, et al.
Publicado: (2020)

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2017)

The current role of circulating biomarkers in non-muscle invasive bladder cancer
por: Rink, Michael, et al.
Publicado: (2019)

Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases
por: Le, Uyen-Thao, et al.
Publicado: (2018)

Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay
por: Belloum, Yassine, et al.
Publicado: (2020)

Author Correction: Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases
por: Le, Uyen-Thao, et al.
Publicado: (2020)

EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients
por: Scharpenseel, Heather, et al.
Publicado: (2019)

Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression
por: Kornfeld, J-W, et al.
Publicado: (2011)

Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases
por: Mohme, Malte, et al.
Publicado: (2017)

Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients
por: Babayan, Anna, et al.
Publicado: (2013)

In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy
por: Chen, Shukun, et al.
Publicado: (2019)

Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients
por: Gorges, Katharina, et al.
Publicado: (2019)

Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
por: Hanssen, Annkathrin, et al.
Publicado: (2018)

Breast surgery: a narrative review
por: Saunders, Christobel M
Publicado: (2022)

Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients
por: Kuske, Andra, et al.
Publicado: (2016)

Clonality of circulating tumor cells in breast cancer brain metastasis patients
por: Riebensahm, Carlotta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_saii60kq0s5rcu0j96fbg96h02